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A B S T R A C T
Purpose
Performance status (PS) is a prognostic factor in patients with metastatic colorectal cancer. Clinical
trials typically enroll less than 10% of patients with a PS of 2 (PS2); thus, the benefit of systemic
chemotherapy in PS2 patients is uncertain.
Patients and Methods
Individual data from 6,286 patients (509 PS2 patients) from nine clinical trials were used to
compare treatment efficacy by PS. Progression-free survival (PFS), grade  3 adverse events,
60-day all-cause mortality, overall survival (OS), and response rate (RR) were explored in the full set
of nine trials and in the five trials comparing first-line monotherapy with combination therapy.
Results
Compared with patients with PS of 0 or 1, PS2 patients had significantly higher rates of grade  3
nausea (8.5% v 16.4%, respectively; P  .0001) and vomiting (7.6% v 11.9%, respectively;
P  .006) and 60-day all-cause mortality (2.8% v 12.0%, respectively; P  .0001). PS2 was
prognostic for PFS (hazard ratio [HR]  1.52; P  .0001; median PFS, 7.6 months for PS 0 or 1 v
4.9 months for PS2), OS (HR  2.18; P  .0001; median OS, 17.3 months for PS 0 or 1 v 8.5
months for PS2), and RR (odds ratio  0.61; P  .0001; 43.8% for PS 0 or 1 v 32.0% for PS2). The
relative benefit and toxicity of experimental versus control treatment and monotherapy versus
combination therapy were not different in PS 0 or 1 patients versus PS2 patients.
Conclusion
In clinical trials, PS2 patients derive similar benefit from superior treatment as patients with PS of 0 to
1 but with an increased risk of toxicities and 12% 60-day mortality. Although current treatment
provides benefit, new approaches are required to approach 1-year median survival for PS2 patients.
J Clin Oncol 27:1948-1955. © 2009 by American Society of Clinical Oncology
INTRODUCTION
Chemotherapy for advanced colorectal cancer pro-
longs time to progression and improves overall sur-
vival (OS) compared with best supportive care.1
Combination chemotherapy of fluorouracil (FU)
with irinotecan or oxaliplatin results in improved
response rate (RR) and prolonged time to progres-
sion compared with single-agent therapy.2-7 Recent
trials of combination chemotherapy, many includ-
ing a biologic agent, have reported median survival
times near 2 years.8-10 Consequently, many clini-
cians consider combination therapy to be standard
of care for first-line treatment of colorectal cancer.
Even among practitioners who favor initial single-
agent therapy, most eventually treat their patients
who are candidates for additional treatment with
combination therapy (usually in the form of FU/
oxaliplatin, FU/irinotecan, or a chemotherapeutic
with a biologic such as bevacizumab or cetuximab)
after treatment failure with single-agent therapy.
However, the favorable outcomes, coupled
with reasonable tolerability of combination therapy,
have been demonstrated in clinical trials that have
typically enrolled a fit population. There has been
limited investigation as to whether the benefit of
improved therapy applies equally to patients with
poor performance status (PS). In most phase III
trials, less than 10% of the study population is com-
prised of patients with an Eastern Cooperative On-
cology Group PS of 2 (PS2).
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The question of whether chemotherapy benefit extends to pa-
tients with poor PS is particularly relevant because PS is an established
strong prognostic factor in advanced colorectal cancer, with the me-
dian survival of PS2 patients being less than half that of patients with
PS of 0 at presentation.11-14 In untreated cancer patients, PS may
decline either because of underlying poor health or because of cancer-
related symptoms. There is some suggestion that in patients with
cancer-related functional decline, FU-based chemotherapy improves
patient PS and health-related quality of life.15 There is also preliminary
evidence from a small study that poor PS patients may tolerate chem-
otherapy.16 However, there is uncertainty about the best treatment
option for poor PS patients when faced with the choice between an
effective but toxic therapy or a gentler alternative. Even less is known
about the influence of underlying ill health on the toxicity and benefit
from chemotherapy of colorectal cancer. Those with noncancer co-
morbidity have an increased risk of death compared with otherwise
healthy colon cancer patients17; yet, at least in the adjuvant setting,
these patients seem to benefit as much from chemotherapy as those
without chronic comorbid illness.18
Thus, the true risks and benefits of chemotherapy in PS2 patients
have not been well studied, making it difficult to counsel the poor PS
patient with regard to the merits of using first-line aggressive chemo-
therapy. In addition, whether treatment with modern chemotherapy
has the potential to overcome the poor prognosis associated with
worse PS at time of presentation is unknown. Given the small num-
bers of PS2 patients enrolling onto clinical trials to answer these
questions, we performed a pooled analysis of clinical trials using FU-
based chemotherapy in conjunction with irinotecan or oxaliplatin for
patients with advanced colorectal cancer. Trials including bevaci-
zumab were not included because the pivotal trials with this agent
either excluded PS2 patients entirely19 or included too few PS2 pa-
tients to provide useful analytic information.20
PATIENTS AND METHODS
Study Design
A protocol-specified retrospective analysis was conducted using in-
dividual patient data from patients with colorectal cancer enrolled onto
nine clinical trials.2,4-8,21-23 Trials included were pivotal phase III clinical
trials of therapy for metastatic colorectal cancer for which trial investiga-
tors agreed to provide individual patient data. Institutional review board
(IRB) approval and informed consent were obtained when patients en-
tered each individual trial. IRB approval for this pooled analysis was
granted by the Mayo Clinic IRB. No attempt was made to gather individual
patient data from all trials conducted within the same time period; there-
fore, results presented should not be interpreted as a meta-analysis of the
value or relative benefit of different chemotherapy regimens. The control
arms for the nine clinical trials included FU plus leucovorin (LV; five
trials); infusional fluorouracil, leucovorin, and oxaliplatin (two trials);
fluorouracil, leucovorin, and oxaliplatin (one trial); and irinotecan, flu-
orouracil, and leucovorin (one trial). Five trials specifically compared
first-linemonotherapywithcombinationtherapy.Multipledifferentchem-
otherapy regimens were used; the specific treatment regimens within each
trial are listed in Table 1. Progression-free survival (PFS) was prespecified
as the primary end point of this analysis, with secondary end points of
grade  3 adverse events, OS, and tumor RR.
Two methods for examining the relative benefit of treatment in Eastern
Cooperative Oncology Group PS 0 to 1 patients versus PS2 patients were
prespecified. The initial approach compared, for each end point, the relative
difference in outcomes between the experimental arm and the control therapy
arm in each trial between PS 0 to 1 patients and PS2 patients. The second
prespecified approach restricted the analysis to only the five trials comparing
initial monotherapy (FU/LV) versus combination therapy. The classification
of each regimen within each study for these two analyses is listed in Table 1.
Statistical Methods
Individual patient data for all randomly assigned patients were included
in the pooled analysis. Safety data on all randomly assigned patients were
summarized for each study by PS group. Logistic regression models were used
to explore the relationship between the incidence of selected severe adverse
events (grade  3) and PS group (0 or 1 v 2), controlling for sex, age, the
patient’s original study, and indicator variables for whether the patient’s treat-
ment included irinotecan and/or oxaliplatin. To determine whether the rela-
tive difference in adverse event rates by arm within study (experimental v
control arms) varied by PS, multivariate logistic regression was used to test for
a PS-treatment interaction while adjusting for main effects, as well as age, sex,
and study. Adverse events were graded using the National Cancer Institute
Common Toxicity Criteria version 2 grading scale. Detailed baseline data on
the underlying cause for poor PS (disease v comorbidity) were not available.










de Gramont et al4
FU/LV 210 10 C M
FOLFOX4 210 10 E D
Douillard et al6
FU/LV 187 7 C M
FOLFIRI 198 7 E D
Seymour et al2
LVFU23CPT 710 9 C M
LVFU23FOLFIRI 356 8 E M
LVFU23FOLFOX 356 9 E M
FOLFIRI 356 8 E D
FOLFOX 357 8 E D
Goldberg et al22
IFL 390 5 C NA
FOLFOX4 386 5 E NA
IROX 383 5 E NA
Köhne et al7
FU/LV 216 4 C M
FUFIRI 214 5 E D
Tournigand et al8
FOLFOX4 310 8 C NA
Stop-and-go
FOLFOX7
306 9 E NA
Porschen et al23
FUFOX 232 8 C NA
CAPOX 239 9 E NA
Saltz et al5
FU/LV 219 14 C M
IFL 225 16 E D
Tournigand et al21
FOLFOX6 113 6 C NA
FOLFIRI 113 17 E NA
Abbreviations: PS2, performance status of 2; E, experimental; C, control; M,
monotherapy; D, doublet; FU, fluorouracil; LV, leucovorin; FOLFOX, infusional
fluorouracil, leucovorin, and oxaliplatin; FOLFIRI, infusional fluorouracil, leuco-
vorin, and irinotecan; CPT, irinotecan; IFL, irinotecan, fluorouracil, and leuco-
vorin; NA, not available; IROX, irinotecan and oxaliplatin; FUFIRI, fluorouracil,
leucovorin, and irinotecan; FUFOX, fluorouracil, leucovorin, and oxaliplatin;
CAPOX, capecitabine plus oxaliplatin.
Considered control group for progression-free survival and response rate
end points.
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Efficacy end points analyzed were PFS, OS, and RR. For the two thera-
peutic comparisons (experimental v control and combination v mono-
therapy), the relative benefit of treatment arms for RR was explored using
logistic regression. For the end points of PFS and OS, all studies were included
in a Cox regression model, stratified for the patient’s original study.24 PFS was
defined as the time to the first event of progression or death. For all end points,
the presence of a treatment-study interaction was tested for by comparing a
model with a single treatment term to a model with a study-specific treatment
effect term using a likelihood ratio test. All logistic and survival models were
adjusted for patient age and sex. PS-treatment interactions were tested using a
likelihood ratio test comparing a model with PS and treatment main effects
terms with a model also including a PS-by-treatment multiplicative factor. All
analyses were conducted using the SAS system version 9.0 (SAS Institute, Cary,
NC); P  .05 was used to denote statistical significance.
RESULTS
A total of 6,286 patients were enrolled onto the nine studies. The trials
included 509 patients (8%) with PS2. PS was relatively well balanced
between treatment arms within each study, and the rate of PS2 pa-
tients by study arm ranged from 4% to 17% (Table 1). The distribu-
tion of age by PS group was similar (PS 0 to 1: median age, 63 years;
range, 19 to 88 years; PS2: median age, 63 years; range, 24 to 84 years;
P  .12). Patients with PS of 0 to 1 were more likely to be male than
PS2 patients (64% v 58%, respectively; P  .0006).
PS was strongly prognostic for efficacy outcomes, regardless of
treatment. The median PFS time for PS 0 to 1 patients was 7.6
months compared with 4.9 months for PS2 patients (hazard ratio
[HR]  1.52; 95% CI, 1.38 to 1.66; P  .0001; Fig 1A). Similarly, the
median OS time for PS 0 to 1 patients was 17.3 months compared with
8.5 months for PS2 patients (HR  2.18; 95% CI, 1.98 to 2.40;
P  .0001; Fig 1B). The tumor RR was significantly lower in PS2
patients as well (32.0%) compared with PS 0 to 1 patients (43.8%;
odds ratio [OR]  0.61; 95% CI, 0.49 to 0.74; P  .0001).
Experimental Versus Control Arms
Focusing initially on the first analysis approach, where within
each trial the relative benefit of experimental versus control treatment
was compared between patients with PS 0 to 1 versus PS2, no differ-
ence in treatment benefit was observed by PS for any efficacy outcome.
In addition, no significant between-trial heterogeneity was observed
between PS and PFS or OS. For PFS, the experimental treatment
provided a benefit in both PS 0 to 1 patients (HR  0.81 for experi-
mental v control treatment; 95% CI, 0.77 to 0.86; P  .00001; median
PFS, 17.9 months for experimental treatment v 16.4 months for con-
trol) and PS2 patients (HR  0.79 for experimental v control treat-
ment; 95% CI, 0.66 to 0.96; P  .02; median PFS, 8.8 months for
experimental treatment v 8.2 months for control). P  .68 for a
PS-treatment interaction, providing no evidence of a differential
treatment benefit by PS (Fig 2). Similarly, for the OS end point, the
experimental treatment provided similar benefit in both PS 0 to 1
patients (HR  0.87; 95% CI, 0.82 to 0.93; P  .00001; median OS, 8.4
months for experimental treatment v 6.7 months for control) and PS2
patients (HR  0.88; 95% CI, 0.73 to 1.07; P  .21; median OS, 6.0
months for experimental treatment v 4.0 months for control). P  .41
for a PS-treatment interaction (Fig 3). Experimental treatment ap-
proximately doubled the likelihood of response in both PS 0 to 1
patients (OR  1.88; 95% CI, 1.68 to 2.10; P  .0001) and PS2 patients
(OR  1.99; 95% CI, 1.29 to 3.05; P  .002), with a PS-treatment
interaction P  .89 (Fig 4).
Monotherapy Versus Combination Therapy
The second analysis restricted the population to the five trials
comparing initial monotherapy with FU/LV with combination ther-
apy. In this subset of 3,814 patients (335 PS2 patients), for the PFS end
point, initial combination treatment provided a benefit in both PS 0 to
1 patients (HR  0.72 for combination v monotherapy; 95% CI, 0.67
to 0.78; P  .0001) and PS2 patients (HR  0.78 for combination v
monotherapy; 95% CI, 0.62 to 0.98; P  .0001). P  .75 for a PS-
treatment interaction (Fig 2). Similarly, for the OS end point, combi-
nation therapy provided similar benefit in both PS 0 to 1 patients
(HR  0.89; 95% CI, 0.82 to 0.96; P  .003) and PS2 patients
(HR  0.79; 95% CI, 0.62 to 0.99; P  .04). P  .18 for a PS-treatment
interaction (Fig 3). Treatment with initial combination therapy com-
pared with monotherapy significantly increased the likelihood of re-
sponse in both PS 0 to 1 patients (OR  2.71; 95% CI, 2.34 to 3.14;
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PS 0-1 (median = 7.6 months)
PS 2 (median = 4.9 months)
P < .0001
HR: 1.52 (95% CI: 1.38 to 1.66)
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HR: 2.18 (95% CI: 1.98 to 2.40)
PS 0-1 (median = 17.3 months)
PS 2 (median = 8.5 months)
Fig 1. (A) Progression-free survival and (B) overall survival by performance
status (PS), regardless of treatment. HR, hazard ratio.
Sargent et al
1950 © 2009 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
P  .0001) and PS2 patients (OR  2.85; 95% CI, 1.61 to 5.02;
P  .0003). P  .71 for a PS-treatment interaction (Fig 4).
Toxicity
Between-study heterogeneity was observed in the rates of
grade  3 adverse events; specifically, the reported adverse event rates
were consistently lower in the FOCUS2 trial compared with the other
included trials. For this reason, the FOCUS trial was excluded for the
primary adverse event analysis. Rates of grade  3 adverse events by PS
group are listed in Table 2. Nausea and vomiting of grade  3 were
significantly more common in PS2 patients (nausea, 8% PS 0 to 1 v
16% PS2, P  .0001; vomiting, 8% PS 0 to 1 v 12% PS2, P  .006). The
rates of stomatitis, diarrhea, and neutropenia did not differ by PS
group. In a secondary analysis including the FOCUS trial, nausea and
vomiting continued to be elevated in PS2 patients (P  .0001 and
P  .0002, respectively). In addition, stomatitis became significantly
elevated in PS2 patients (2% PS 0 to 1 v 4% PS2, P  .03).
We conducted further analyses to determine whether the relative
difference in adverse event rates by arm within study (experimental v
control arms) varied by PS. Specifically, we tested for a PS-treatment
interaction, which, if significant, would imply that the relative increase
in adverse event rates from a more toxic versus a less toxic regimen
depends on patient PS. In these models, the P value for a PS-treatment
interaction was nonsignificant at the .05 level for any adverse event,
indicating that any differential toxicity in experimental versus control
treatments is not PS dependent. The PS-treatment interaction P values
remained nonsignificant for the secondary analysis when the FOCUS
trial was included.
The rate of death in the first 60 days from random assignment
from any cause was significantly different by PS group, with a rate of
3% in PS 0 to 1 patients compared with 12% in PS2 patients
(P  .0001). In the PS2 patients, 54% of these early deaths were
preceded by disease progression, suggesting that the difference in
60-day all cause mortality is likely a result of more aggressive disease in
PS2 patients, other comorbid disease beyond the patients’ malig-
nancy, and potential toxic effects of therapy.
DISCUSSION
This pooled analysis demonstrates that patients with advanced colo-
rectal cancer who present for first-line chemotherapy on clinical trials
0 0.5 1 1.5 2 2.5 3 3.5 4
     Events/Patients
Control Experimental HR 95% CI
De Gramont
147/176 138/177 0.68       (0.54 to 0.85)
21/21 16/21 0.53       (0.27 to 1.03)
Douillard
143/164 135/167 0.72        (0.57 to 0.92)
13/13 11/12 1.15        (0.45 to 2.97)
FOCUS (Initial LV5FU2 v Initial FOLFIRI)
1,182/1,231 296/314 0.75        (0.66 to 0.85)
107/109 26/26 0.77        (0.51 to 1.16)
FOCUS (Initial LV5FU2 v Initial FOLFOX)
1,182/1,231 298/313 0.73        (0.65 to 0.83)
107/109 28/28 0.64        (0.43 to 0.96)
Goldberg (IFL v FOLFOX4)
341/370 326/364 0.71        (0.61 to 0.83)
18/18 19/20 0.42        (0.21 to 0.85)
Goldberg (IFL v IROX)
341/370 337/362 0.97        (0.83 to 1.13)
18/18 18/20 0.43        (0.21 to 0.87)
Kohne
189/193 177/189 0.66        (0.54 to 0.80)
8/8 8/8 0.34        (0.11 to 0.99)
OPTIMOX
251/281 253/276 1.06        (0.89 to 1.26)
23/25 21/23 0.87        (0.47 to 1.60)
Porschen
168/197 177/199 1.23        (1.00 to 1.51)
16/17 17/19 1.01        (0.51 to 1.97)
Saltz
174/187 160/188 0.77        (0.62 to 0.96)
29/29 32/32 1.26        (0.73 to 2.16)
Tournigand
82/101 77/85 1.16        (0.84 to 1.60)
6/6 16/17 1.22        (0.43 to 3.45)
Mono v Combo Subset
1,923/2,059 1,258/1,420 0.72        (0.67 to 0.78)
193/195 133/140 0.78        (0.62 to 0.98)
Overall (Control v Experimental)
2,786/3,036 2,450/2,741 0.81        (0.77 to 0.86)
256/263 231/246 0.79        (0.66 to 0.96)
PS 0-1
PS 2
Hazard Ratio (HR) 
Fig 2. Forest plot of study-specific progression-free survival (PFS) hazard ratios (HR) by performance status (PS). FU, fluorouracil; LV, leucovorin; FOLFIRI, infusional
fluorouracil, leucovorin, and irinotecan; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; IFL, irinotecan, fluorouracil, and leucovorin; IROX, irinotecan and oxaliplatin.
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with a PS of 2 benefit just as much from modern chemotherapy
regimens as do patients with a PS of 0 or 1. In particular, the relative
benefit of experimental and combination regimens was the same in
PS2 patients compared with PS 0 to 1 patients. Unfortunately, despite
the benefit provided to PS2 patients by newer combination therapy,
the OS of PS2 patients (median OS, 8.5 months) treated with any
of the regimens remained substantially shorter than the OS of PS 0 to
1 patients treated with inferior regimens. In addition, although PS2
patients receive benefit from modern treatment, severe nausea and
vomiting were much more pronounced in PS2 patients than in PS 0 to
1 patients. However, there was no differential increase in toxicity in
PS2 patients from the more intensive and potentially more toxic
regimens, suggesting that the higher rate of toxicity may be from
underlying illness rather than a more profound adverse effect profile
experienced by PS2 patients from the more toxic regimens. Sixty-day
mortality was also markedly higher in PS2 patients, although much of
this was likely related to rapid disease progression or existing comor-
bidity rather than toxicity.
The benefit of the experimental and combination regimens in
PS2 patients in this pooled analysis is of direct clinical relevance be-
cause these arms included the currently used, modern combinations.
Although the relative benefit of modern combination therapy seems
to be independent of PS, the median OS and PFS times of PS2 patients
are less than half of those of PS 0 to 1 patients. Consequently, the
absolute benefit afforded by these combination regimens is smaller,
which is an observation that has some bearing when considering the
higher incidence of severe nausea and vomiting from treatment and
the high 60-day mortality experienced by PS2 patients. An important
question that cannot be answered by this analysis is whether these
same PS2 patients may have felt just as poorly, or worse, if treated with
supportive care only. In patients with poor PS as a result of their
cancer, health-related quality of life is likely poor before initiation of
therapy, and nausea and/or vomiting may already be present. The lack
of a treatment-PS interaction in our toxicity analysis suggests that PS
0 to 1 and PS2 patients experience a similar increase in adverse
events with more toxic therapy. Thus, the higher rate of toxicity in
PS2 patients is likely more influenced by the patients’ pre-existing
poor health than the treatment regimen chosen.
One limitation of this study is that we were unable to distinguish
between patients whose poor PS was a direct result of their cancer or a
PS 0-1
PS 2
Hazard Ratio (HR) 
     Events/Patients
Control Experimental HR
De Gramont
110/188 104/188 0.87       (0.66 to 1.13)
21/22 16/22 0.54       (0.27 to 1.08)
Douillard
122/173 116/185 0.80       (0.62 to 1.04)
14/14 10/13 0.56       (0.21 to 1.47)
FOCUS* (LV5FU2 -> FOLFIRI)
544/649 276/328 0.96       (0.83 to 1.11)
57/61 24/28 0.76       (0.47 to 1.24)
FOCUS* (Initial FOLFIRI)
544/649 265/326 0.87       (0.75 to 1.01)
57/61 27/30 0.57       (0.35 to 0.93)
FOCUS* (LV5FU2 -> FOLFOX)
544/649 280/325 0.92       (0.80 to 1.07)
57/61 30/31 1.64       (1.03 to 2.62)
FOCUS* (Initial FOLFOX)
544/649 281/327 0.94       (0.81 to 1.08)
57/61 29/30 0.75       (0.47 to 1.18)
Goldberg (IFL v FOLFOX4)
327/372 280/366 0.66       (0.56 to 0.78)
17/18 19/20 0.74       (0.36 to 1.52)
Goldberg (IFL v IROX)
327/372 315/363 0.89       (0.76 to 1.04)
17/18 19/20 0.74       (0.38 to 1.43)
Kohne
157/207 149/204 0.89       (0.71 to 1.12)
9/9 7/10 0.69       (0.25 to 1.92)
OPTIMOX
209/285 199/280 0.92       (0.76 to 1.12)
21/25 22/26 0.88       (0.47 to 1.67)
Porschen
118/214 134/218 1.13       (0.88 to 1.45)
13/18 17/21 0.95       (0.45 to 1.99)
Saltz
150/189 130/190 0.77       (0.61 to 0.97)
30/30 34/35 1.30       (0.76 to 2.24)
Tournigand
60/106 48/94 0.87       (0.59 to 1.29)
6/7 17/19 0.79       (0.28 to 2.26)
Mono v Combo Subset
1,083/1,406 1,601/2,073 0.89       (0.82 to 0.96)
131/136 177/199 0.79       (0.62 to 0.99)
Overall (Control v Experimental)
1,797/2,383 2,577/3394 0.87       (0.82 to 0.93)
188/204 271/305 0.88       (0.73 to 1.07)
0 0.5 1 1.5 2 2.5 3
95% CI
Fig 3. Forest plot of study-specific overall survival hazard ratios (HR) by performance status (PS). FU, fluorouracil; LV, leucovorin; FOLFIRI, infusional fluorouracil,
leucovorin, and irinotecan; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; IFL, irinotecan, fluorouracil, and leucovorin; IROX, irinotecan and
oxaliplatin; CPT, irinotecan.
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result of medical comorbidity. Given the two- to three-fold increase in
the odds of response in PS2 patients, the choice of a superior regimen
with a higher probability of tumor regression and associated relief of
cancer symptoms has the potential to improve quality of life in pa-
tients whose PS decline is a result of cancer. In contrast, patients with
poor PS as a result of comorbid medical conditions may be less likely
to improve or perhaps more likely to suffer severe adverse effects and
further PS decline from combination therapy. Accordingly, if one is to
treat patients with poor PS as a result of their cancer, a more aggressive
regimen may be justified with a goal of improving cancer-related
symptoms and preventing further deterioration of PS. The converse,
however, may be true of those with poor PS from other comorbid
medical conditions. Unfortunately, our analysis cannot distinguish
between these two groups of poor PS patients because no data were
collected on the reason underlying poor PS at enrollment and current
methodologies to assess PS inadequately address this issue, highlight-
ing the need for research to better define comorbidity in future trials.
A second limitation of our study is that we cannot tell to what
extent the PS2 patients selected for inclusion in these clinical trials are
representative of poor PS patients in the whole population. Because
investigators may be more likely to enroll patients with PS decline
from cancer rather than from chronic disease who have borderline PS
onto a clinical trial, we suspect that many of the PS2 patients included
in this analysis had PS decline from cancer.
On the basis of these results, oncologists can feel confident that
treating patients who present with poor PS as a result of their cancer
95% CI
Odds Ratio (OR) 
     Events/Patients
Control Experimental OR
De Gramont
44/176 92/177 3.25        (2.07 to 5.11)
2/21 11/21  10.35       (1.86 to 57.47)
Douillard
40/164 67/167 2.12        (1.32 to 3.41)
1/13 2/12  4.23        (0.20 to 90.81)
FOCUS (Initial LV5FU2 v Initial FOLFIRI)
394/1,231 168/314 2.44        (1.90 to 3.14)
25/109 9/26 1.97        (0.76 to 5.11)
FOCUS (Initial LV5FU2 v Initial FOLFOX)
394/1,231 185/313 3.05        (2.36 to 3.94)
25/109 14/28 3.51        (1.46 to 8.43)
Goldberg (IFL v FOLFOX4)
142/370 186/364 1.69        (1.26 to 2.27)
2/18 7/20  4.46        (0.77 to 25.92)
Goldberg (IFL v IROX)
142/370 131/362 0.91        (0.67 to 1.23)
2/18 8/20  5.99        (1.02 to 35.32)
Kohne
65/193 113/189 2.93        (1.93 to 4.45)
3/8 3/8  1.09        (0.10 to 11.47)
OPTIMOX
165/281 169/276 1.11        (0.79 to 1.57)
16/25 13/23 0.73        (0.22 to 2.40)
Porschen
114/197 106/199 0.81        (0.54 to 1.21)
10/17 8/19 0.57        (0.13 to 2.48)
Saltz
46/187 86/188 2.69        (1.72 to 4.21)
2/29 4/32  3.50        (0.46 to 26.51)
Tournigand
57/101 52/85 1.24        (0.67 to 2.28)
2/6 9/17  3.52        (0.41 to 30.56)
Mono v Combo Subset
589/1,951 711/1,348 2.71        (2.34 to 3.14)
33/180 43/127 2.85        (1.61 to 5.02)
Overall (Control v Experimental)
1,067/2,900 1,355/2,634 1.88        (1.68 to 2.10)
63/246 88/226 1.99        (1.29 to 3.05)
0 2 4 6 8 10 12
PS 0-1
PS 2
Fig 4. Forest plot of study-specific response rate odds ratios (OR) by performance status (PS). FU, fluorouracil; LV, leucovorin; FOLFIRI, infusional fluorouracil,
leucovorin, and irinotecan; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; IFL, irinotecan, fluorouracil, and leucovorin; IROX, irinotecan and oxaliplatin.
Table 2. Patients Who Experienced NCI-CTC Grade 3 or Greater Adverse
Events (excluding FOCUS trial)
Grade 3 Events
% of Patients
P Overall PS 0-1 PS2
Nausea 9.1 8.5 16.4  .0001
Vomiting 8.0 7.6 11.9 .006
Diarrhea 16.9 17.1 14.9 .32
Stomatitis 2.5 2.3 5.0 .11
Neutropenia 33.7 33.7 34.5 .51
Abbreviations: NCI-CTC, National Cancer Institute Common Toxicity Criteria;
PS, performance status.
P from a logistic regression for PS as a dichotomous variable (PS 0-1 v PS2)
in a model controlling for study, sex, age, and indicators for whether treatment
included irinotecan and/or oxaliplatin.
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with maximally effective chemotherapy is likely to provide patient
benefit; however, regardless of regimen, these patients need to be
managed attentively with supportive care. It is unclear from these
results whether the addition of biologic agents is similarly beneficial in
PS2 patients. Although the biologic agents approved for use in colo-
rectal cancer (bevacizumab, cetuximab, and panitumumab) are gen-
erally well tolerated, the addition of biologics to chemotherapy clearly
increases the incidence of severe adverse events.19,24,25 Thus, if a bio-
logic is used in addition to chemotherapy for the treatment of PS2
patients, careful monitoring for toxicity is warranted.
The benefit of modern chemotherapy for advanced colorectal
cancer applies not only to fit, young patients, but also to the elderly26,27
and, now, to patients with poor PS. However, the survival of patients
with poor PS, even with recent advances, continues to be quite poor. A
better understanding of host and tumor biology that leads some to
present with cancer once already rather ill and to die quickly thereafter
will be necessary to improve the survival of these sickest of colorectal
cancer patients.
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Henning Köhne, Matthew T. Seymour, Aimery de Gramont, Rainer
Porschen, Leonard B. Saltz, Philippe Rougier, Christophe Tournigand,
Jean-Yves Douillard, Richard J. Stephens, Richard M. Goldberg
Collection and assembly of data: Daniel J. Sargent, Claus Henning
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